Loading…
Bone Biologics Corporation is projected to decline to $1.37 by 2027, a -2% move from its current price of $1.39. BBLG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.35 | $1.39 | $1.44 | -0.01% |
| Jul 15 | $1.33 | $1.39 | $1.45 | -0.02% |
| Jul 16 | $1.31 | $1.39 | $1.47 | -0.04% |
| Jul 17 | $1.30 | $1.39 | $1.48 | -0.05% |
| Jul 18 | $1.29 | $1.39 | $1.49 | -0.06% |
| Jul 19 | $1.28 | $1.39 | $1.50 | -0.07% |
| Jul 20 | $1.28 | $1.39 | $1.51 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.28 | $1.39 | $1.51 | -0.08% |
| Week 2 | $1.23 | $1.39 | $1.57 | -0.17% |
| Week 3 | $1.20 | $1.39 | $1.61 | -0.25% |
| Week 4 | $1.17 | $1.39 | $1.64 | -0.34% |
| Week 5 | $1.14 | $1.38 | $1.67 | -0.42% |
| Week 6 | $1.12 | $1.38 | $1.70 | -0.50% |
| Week 7 | $1.10 | $1.38 | $1.73 | -0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using a recombinant human protein in the United States. Its lead product is the NELL-1/DBM medical device, an osteopromotive recombinant protein that provides target-specific control over bone regeneration.
The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine.
The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Bone Biologics Corporation (BBLG) is a healthcare stock trading at $1.44 per share with a market cap of $2.59M. It ranks 5439 by market capitalization.
The 30-day technical picture is bullish, with RSI(14) at 70, and moving averages showing proximity to upside resistance. The 50-day simple moving average stands at $1.29, while the 200-day simple moving average is $1.65. Immediate support sits at $1.22 and resistance at $1.44, with a 30-day trading range of $1.15 to $1.81.
Forecasts imply a multi-year path of upside, with average prices rising from $1.44 in 2026 to $4.93 in 2050 and maximums climbing to $9.98 by 2050. The projected ROI progresses from 0 in 2026 to a high of 242.1 by 2050, with sentiment transitioning to bullish in the later years.
A major floor 22.3% below — a decisive break under it would weaken the trend.
The nearest floor, 11.5% below — buyers have tended to step in here.
The nearest ceiling, 5.8% above — a clean break opens room to run.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key BBLG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBLG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.40 | Sell | $1.39 | Sell |
| MA 10 | $1.40 | Sell | $1.39 | Sell |
| MA 20 | $1.39 | Buy | $1.37 | Buy |
| MA 50 | $1.32 | Buy | $1.34 | Buy |
| MA 100 | $1.28 | Buy | $1.39 | Sell |
| MA 200 | $1.58 | Sell | $2.27 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.87 | Neutral |
| Stoch RSI (14) | 31.31 | Neutral |
| CCI (20) | 7.84 | Neutral |
| Williams %R (14) | -61.54 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 0.72 | Buy |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 38.46 | Neutral |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 50.57 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 1.38 | Buy |
| ADX (14) | 12.65 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day picture shows a bullish tilt. RSI(14) is 70, indicating current strength but potential for consolidation near the top of the range. The stock trades above the near-term support level of $1.22, with resistance at $1.44.
The 30-day range runs from $1.15 to $1.81, suggesting trading within a modestly wide band for the moment. The 50-day SMA is $1.29 and the 200-day SMA is $1.65, highlighting a mild upward tilt in the longer trend alongside the current strength.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.08 | $1.39 | $1.71 | 0% | Neutral | |
| $1.07 | $1.37 | $1.86 | -2% | Neutral | |
| $1.33 | $1.76 | $2.49 | +26% | Bullish | |
| $1.48 | $2.01 | $2.94 | +44% | Bullish | |
| $1.39 | $1.94 | $2.92 | +39% | Bullish | |
| $1.47 | $2.10 | $3.24 | +51% | Bullish | |
| $1.39 | $2.02 | $3.19 | +46% | Bullish | |
| $1.37 | $2.03 | $3.26 | +46% | Bullish | |
| $1.73 | $2.61 | $4.28 | +88% | Bullish | |
| $1.82 | $2.81 | $4.68 | +102% | Bullish | |
| $2.33 | $3.90 | $6.96 | +181% | Bullish | |
| $2.98 | $5.79 | $11.41 | +316% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.08 | $1.39 | $1.71 | +0.00% |
| August 2026 | $1.18 | $1.40 | $1.72 | +1.05% |
| September 2026 | $1.15 | $1.37 | $1.70 | -2.12% |
| October 2026 | $1.17 | $1.41 | $1.77 | +2.66% |
| November 2026 | $1.16 | $1.41 | $1.78 | -0.12% |
| December 2026 | $1.10 | $1.35 | $1.71 | -4.55% |
Click any year to see its month-by-month BBLG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BBLG is projected to trade between $1.08 and $1.71, averaging $1.39 — a potential gain of 0% from today's $1.39. Price action looks broadly range-bound.
Bone Biologics Corporation's 2027 outlook centres on $1.37, within a $1.07 to $1.86 range. That is -2% versus the projected 2026 average. That marks a -2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, BBLG could reach as high as $2.49, with a base case around $1.76 and support toward $1.33 — roughly +26% from $1.39. Momentum favours further upside here.
Expect BBLG to range from $1.48 to $2.94 through 2029. The $2.01 average target implies a +44% move from current prices. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BBLG price prediction for 2030 points to an average of $1.94 (low $1.39, high $2.92) — a potential gain of +39% on today's $1.39. Momentum favours further upside here.
In 2031, BBLG is projected to trade between $1.47 and $3.24, averaging $2.10 — a potential gain of +51% from today's $1.39. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Bone Biologics Corporation's 2032 outlook centres on $2.02, within a $1.39 to $3.19 range. That is -4% versus the projected 2031 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2033, BBLG could reach as high as $3.26, with a base case around $2.03 and support toward $1.37 — roughly +46% from $1.39. Buyers look set to stay in control over this stretch.
Expect BBLG to range from $1.73 to $4.28 through 2034. The $2.61 average target implies a +88% move from current prices. That is up +29% on the projected 2033 average. Momentum favours further upside here.
The BBLG price prediction for 2035 points to an average of $2.81 (low $1.82, high $4.68) — a potential gain of +102% on today's $1.39. Buyers look set to stay in control over this stretch.
In 2040, BBLG is projected to trade between $2.33 and $6.96, averaging $3.90 — a potential gain of +181% from today's $1.39. That is up +39% on the projected 2035 average. Momentum favours further upside here.
Bone Biologics Corporation's 2050 outlook centres on $5.79, within a $2.98 to $11.41 range. That is up +48% on the projected 2040 average. That marks a +316% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BBLG today (≈ 719.42446 BBLG) could be worth
$4,164.65
+$3,164.65 (+316%) by 2050 · US Dollar
Based on the average projected BBLG price of $5.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBLGwould be worth at today's price.
$1,000 invested in BBLG on Jul 10, 2025 (≈ 331.12583 BBLG) would be worth
$460.26
-$539.74 (-54.0%) today · 0.46× · US Dollar
Based on a BBLG entry price of $3.02 vs. today's $1.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.42 | $978.87 | -2.1% |
| 1 month ago | $1.24 | $1,120.97 | +12.1% |
| 3 months ago | $1.26 | $1,103.17 | +10.3% |
| 6 months ago | $1.65 | $842.42 | -15.8% |
| 1 year ago | $3.02 | $460.26 | -54.0% |
| All time (4.7y) ago | $7,329.6 | $0.19 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBLG forecast.
Our base-case forecast reaches $2.80 around 2035.
Implied market cap at $2.80: $5.03M
The multi-year forecast portrays a steady-to-accelerating ascent, especially after the late-2020s. In 2029 the average price is $1.93 with a max of $2.87 and ROI of 33.8, followed by continued bullish momentum through 2030 (avg $1.91, max $2.92, ROI 32.4) and 2031 (avg $1.93, max $3.03, ROI 33.8).
Beyond the mid-2030s, the outlook strengthens: 2034 avg $2.26, max $3.78, ROI 57.1; 2035 avg $2.59, max $4.40, ROI 79.7. The forecast peaks later in the horizon, with 2040 avg $3.28, max $5.99, ROI 127.6, and 2050 avg $4.93, max $9.98, ROI 242.1. Sentiment is bullish from 2029 onward, reflecting the longer-term growth embedded in the projections.
Key drivers and risks are not described beyond the numeric outlook. The early years show flatter or neutral readings (2026 ROI 0, 2027 ROI -1.2), underscoring a period of uncertainty before the stronger multi-year upside materializes.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $1.91 and a max of $2.92, with an ROI of 32.4 and a bullish outlook.
The forecast displays neutral signals in 2026 (avg $1.44, ROI 0) and 2027 (avg $1.42, ROI -1.2), followed by bullish momentum from 2028 onward, with the 2030–2050 period showing continued upside and a 2050 max of $9.98 (avg $4.93, ROI 242.1). These are estimates, not guarantees.
Yes. The forecast lists a max of $9.98 for 2050, with an average of $4.93 and ROI 242.1, in a bullish long-term scenario.
Sentiment: BULLISH. RSI(14) 70; SMA50 $1.29; SMA200 $1.65; support $1.22; resistance $1.44; 30-day range $1.15–$1.81.
Current price is $1.44 and market cap is $2.59M; the stock ranks 5439.
Bone Biologics Corporation Community Discussion
0Share your Bone Biologics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.